8-K
BIOLIFE SOLUTIONS INC (BLFS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2024
BioLife Solutions, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36362 | 94-3076866 |
|---|---|---|
| (State or other jurisdiction of<br> incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
3303 Monte Villa Parkway,
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (425) 402-1400
| N/A |
|---|
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | BLFS | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On November 12, 2024, BioLife Solutions, Inc. (the “Company”) issued a press release announcing unaudited financial results and operational highlights for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release, dated November 12, 2024 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioLife Solutions, Inc. | ||
|---|---|---|
| Date: November 12, 2024 | By: | /s/ Troy Wichterman |
| Name: Troy Wichterman | ||
| Title: Chief Financial Officer |
Document
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BioLife Solutions Reports Third Quarter 2024 Financial Results
Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023
GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54%
GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20%
Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture
Conference call begins at 4:30 p.m. Eastern time today
BOTHELL, Wash. (November 12, 2024) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, today announced financial results for the three and nine months ended September 30, 2024 and updated revenue guidance for 2024.
“I’m pleased to report our fourth consecutive quarter of sequential Cell Processing revenue growth and expansion of adjusted gross and adjusted EBTIDA margins,” said Roderick de Greef, BioLife Chairman and CEO. “With Q3 now in the books and with good visibility into Q4, we are increasing our projected 2024 Cell Processing revenues by $2 million above our previous guidance. Adjusting for the absence of revenue from the sale of our SciSafe biostorage business, this puts the total revenue for 2024 in the range of $98.0 to $100.0 million.”
de Greef continued, “The sale of our SciSafe biostorage business for $73 million in cash is a major step in our efforts to focus our energy and capital allocation toward our proprietary, high growth and high margin cell processing products. BioLife is now a pure play enabler of CGT’s globally and with a fortified balance sheet, and a streamlined operational environment, we can better focus on our unique biopreservation market leadership position to drive revenue growth and profitability in 2025 and beyond.”
Third Quarter 2024 Business Highlights
•Processed 16 new U.S. FDA Master File cross references for our biopreservation media, bringing the cumulative total processed to 744.
•Based on two additional regulatory approvals in the third quarter, our biopreservation media is embedded in 17 unique commercial CGT's as of September 30, 2024, with an expectation that 6 additional product approvals, geographic expansions, or new indications will occur in the next 12 months.
•On November 12, 2024, we completed the sale of SciSafe Holdings, Inc. (“SciSafe”), a previously wholly owned biostorage and services subsidiary, for $73.0 million in cash.
Third Quarter 2024 Financial Performance
BioLife Solutions is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife Solutions is
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
presenting adjusted (non-GAAP) metrics on a consolidated basis and also presenting its non-GAAP financial metrics excluding the financial results of GCI from its consolidated results. Reconciliations of GAAP to non-GAAP metrics appear at the end of this news release.
REVENUE
•Total revenue for the third quarter of 2024 was $30.6 million, an increase of $7.0 million, or 30%, from $23.6 million for the third quarter of 2023 and up $2.2 million, or 8%, sequentially from the second quarter of 2024.
◦Cell Processing platform revenue was $19.0 million, an increase of $5.7 million, or 43%, from the same period in 2023 and up $1.0 million, or 6%, sequentially from the second quarter of 2024.
◦Biostorage Services platform revenue was $7.5 million, an increase of $0.9 million, or 14%, from the same period in 2023 and up $0.6 million, or 8%, sequentially from the second quarter of 2024.
◦Freezers and Thaw Systems platform revenue was $4.0 million, an increase of $0.4 million, or 11%, from the same period in 2023 and up $0.6 million, or 19%, sequentially from the second quarter of 2024.
•Total revenue for the nine months ended September 30, 2024 was $85.7 million, an increase of $3.7 million, or 4%, from the same period in 2023.
◦Cell Processing platform revenue for the nine months ended September 30, 2024 was $53.2 million, an increase of $2.2 million, or 4%, from the same period in 2023.
◦Biostorage Services platform revenue was $21.6 million, an increase of $2.3 million, or 12%, from the same period in 2023 .
◦Freezers and Thaw Systems platform revenue was $10.9 million, a decrease of $0.9 million, or 7%, from the same period in 2023.
GROSS MARGIN
•Gross margin (GAAP) for the third quarter of 2024 was 51% compared with 48% for the third quarter of 2023. Adjusted gross margin (non-GAAP) for the third quarter of 2024 was 54% compared with 44% for the third quarter of 2023.
•Gross margin (GAAP) for the nine months ended September 30, 2024 was 51% compared with 42% for the same period in 2023. Adjusted gross margin (non-GAAP) for the nine months ended September 30, 2024 was 53% compared with 46% for the same period in 2023.
OPERATING LOSS FROM CONTINUING OPERATIONS
•Operating loss from continuing operations (GAAP) for the third quarter of 2024 was $1.6 million compared with $15.5 million for the third quarter of 2023. Adjusted operating loss from continuing operations (non-GAAP) for the third quarter of 2024 was $0.6 million compared with $8.3 million for the third quarter of 2023.
Page 2
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
•Operating loss from continuing operations (GAAP) for the nine months ended September 30, 2024 was $8.5 million compared with $34.7 million for the same period in 2023. Adjusted operating loss from continuing operations (non-GAAP) for the nine months ended September 30, 2024 was $5.8 million compared with $19.7 million for the same period in 2023.
NET LOSS FROM CONTINUING OPERATIONS
•Net loss from continuing operations (GAAP) for the third quarter of 2024 was $1.7 million compared with $15.8 million for the third quarter of 2023. Adjusted net loss from continuing operations (non-GAAP) for the third quarter of 2024 was $0.8 million compared with $8.5 million for the third quarter of 2023.
•Net loss from continuing operations (GAAP) for the nine months ended September 30, 2024 was $13.1 million, which includes a $4.1 million write-off of our iVexSol equity investment, compared with $30.0 million for the same period in 2023. Adjusted net loss from continuing operations (non-GAAP) for the nine months ended September 30, 2024 was $6.2 million compared with $20.0 million for the same period in 2023.
LOSS PER SHARE FROM CONTINUING OPERATIONS
•Loss per share from continuing operations (GAAP) for the third quarter of 2024 was $0.04 compared with $0.36 for the third quarter of 2023.
•Loss per share from continuing operations (GAAP) for the nine months ended September 30, 2024 was $0.28 compared with $0.69 for the same period in 2023.
ADJUSTED EBITDA
•Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2024 was $6.1 million, or 20% of revenue, compared with $1.4 million, or 6% of revenue, for the third quarter of 2023.
•Adjusted EBITDA, a non-GAAP measure, for the nine months ended September 30, 2024 was $14.6 million, or 17% of revenue, compared with $5.2 million, or 6% of revenue, for the same period in 2023.
CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES
•Cash, cash equivalents, and marketable securities as of September 30, 2024, were $39.3 million.
(As a result of showing amounts in millions, rounding difference may exist in the percentages above.)
2024 Revenue Guidance
BioLife Solutions is revising its 2024 revenue guidance to $98.0 million to $100.0 million from prior guidance of $99.0 million to $101.0 million primarily to reflect the revenue impact of the divestiture of SciSafe on November 12, 2024. This guidance also reflects updated expectations for BioLife's Cell Processing product line and Biostorage and Services, which includes results from its ThawSTAR® product line and does not include revenue from the freezer product line (GCI and CBS) or SciSafe after November 12, 2024.
Page 3
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
•Cell Processing platform revenue: Increased to $72.0 million to $73.0 million from prior guidance of $70.0 million to $71.0 million. The revised guidance represents an increase of 9% to 11% compared with 2023. Compared with the annualized run rate for the second half of 2023, the revised guidance reflects growth of 28% to 30%.
•Biostorage Services platform revenue: Revised to $26.0 million to $27.0 million from prior guidance of $29.0 million to $30.0 million. The revised guidance represents a decrease of 7% to 4% compared with 2023 due to the sale of SciSafe on November 12, 2024. This platform includes the ThawSTAR automated thawing product line. Excluding ThawSTAR, the growth rate is 1% to 4%.
Management expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024.
Page 4
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
Conference Call & Webcast
Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 833-630-0431 or 412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.
About BioLife Solutions
BioLife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy (CGT) market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, storage and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.
Cautions Regarding Forward Looking Statements
Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.
We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating
Page 5
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.
While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com
Page 6
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement (the “Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Purchase Agreement, on April 17, 2024, Global Cooling business is presented in the unaudited condensed financial statements as a discontinued operation for all periods presented. All amounts included in this earnings release relate to continuing operations unless otherwise noted.
BIOLIFE SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except share and per share amounts)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands, except per share and share data) | 2024 | 2023 | 2024 | 2023 | ||||
| Product revenue | $ | 23,457 | $ | 17,137 | $ | 64,624 | $ | 63,444 |
| Service revenue | 4,660 | 4,377 | 14,173 | 12,573 | ||||
| Rental revenue | 2,454 | 2,059 | 6,881 | 5,975 | ||||
| Total product, rental, and service revenue | 30,571 | 23,573 | 85,678 | 81,992 | ||||
| Costs and operating expenses: | ||||||||
| Cost of product, rental, and service revenue (exclusive of Intangible asset amortization) | $ | 14,276 | $ | 11,578 | $ | 40,278 | $ | 44,989 |
| General and administrative | 11,351 | 10,813 | 33,953 | 37,568 | ||||
| Sales and marketing | 3,543 | 4,876 | 10,401 | 12,731 | ||||
| Research and development | 2,050 | 3,739 | 6,827 | 10,772 | ||||
| Asset impairment charges | — | 8,310 | — | 8,310 | ||||
| Intangible asset amortization | 910 | 1,312 | 2,734 | 4,135 | ||||
| Change in fair value of contingent consideration | — | (1,580) | — | (1,778) | ||||
| Total operating expenses | 32,130 | 39,048 | 94,193 | 116,727 | ||||
| Operating loss | (1,559) | (15,475) | (8,515) | (34,735) | ||||
| Other (expense) income: | ||||||||
| Change in fair value of equity investments | — | — | (4,074) | — | ||||
| Gain on settlement of Global Cooling escrow | — | — | — | 5,115 | ||||
| Interest expense, net | (267) | (449) | (796) | (1,216) | ||||
| Other income | 95 | 235 | 417 | 1,002 | ||||
| Total other (expense) income, net | (172) | (214) | (4,453) | 4,901 | ||||
| Loss before income tax benefit (expense) | (1,731) | (15,689) | (12,968) | (29,834) | ||||
| Income tax benefit (expense) | 28 | (115) | (93) | (209) | ||||
| Net loss from continuing operations | $ | (1,703) | $ | (15,804) | $ | (13,061) | $ | (30,043) |
| Discontinued operations: |
Page 7
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
| Loss from discontinued operations | — | (13,328) | (19,572) | (22,999) | ||||
|---|---|---|---|---|---|---|---|---|
| Income tax expense | — | — | (10) | (3) | ||||
| Loss from discontinued operations | $ | — | $ | (13,328) | $ | (19,582) | $ | (23,002) |
| Net loss | $ | (1,703) | $ | (29,132) | $ | (32,643) | $ | (53,045) |
| Loss from continuing operations, attributable to common shareholders: | ||||||||
| Basic and Diluted | $ | (1,703) | $ | (15,804) | $ | (13,061) | $ | (30,043) |
| Loss from discontinued operations, attributable to common shareholders: | ||||||||
| Basic and Diluted | $ | — | $ | (13,328) | $ | (19,582) | $ | (23,002) |
| Loss per share from continuing operations, attributable to common shareholders: | ||||||||
| Basic and Diluted | $ | (0.04) | $ | (0.36) | $ | (0.28) | $ | (0.69) |
| Loss per share from discontinued operations, attributable to common shareholders: | ||||||||
| Basic and Diluted | $ | — | $ | (0.31) | $ | (0.43) | $ | (0.53) |
| Net loss attributable to common shareholders: | ||||||||
| Basic and Diluted | $ | (1,703) | $ | (29,132) | $ | (32,643) | $ | (53,045) |
| Net loss per share attributable to common shareholders: | ||||||||
| Basic and Diluted | $ | (0.04) | $ | (0.67) | $ | (0.71) | $ | (1.22) |
| Weighted average shares used to compute loss per share attributable to common shareholders: | ||||||||
| Basic and Diluted | 46,175,345 | 43,570,438 | 45,871,715 | 43,348,412 |
Page 8
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BIOLIFE SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, amounts in thousands)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||
| Net loss | $ | (1,703) | $ | (29,132) | $ | (32,643) | $ | (53,045) |
| Other comprehensive income (loss) | 347 | (161) | 137 | 19 | ||||
| Comprehensive loss | $ | (1,356) | $ | (29,293) | $ | (32,506) | $ | (53,026) |
BIOLIFE SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION
(Unaudited, amounts in thousands)
| September 30, | December 31, | |||
|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | ||
| Cash, cash equivalents, and marketable securities | $ | 39,256 | $ | 50,184 |
| Working capital | 57,217 | 78,426 | ||
| Current assets | 89,383 | 105,235 | ||
| Current assets, discontinued operations | — | 15,369 | ||
| Current liabilities | 32,166 | 29,382 | ||
| Current liabilities, discontinued operations | — | 12,796 | ||
| Total assets | 381,652 | 412,714 | ||
| Long-term obligations, discontinued operations | — | 1,027 | ||
| Long-term obligations | 24,025 | 31,846 | ||
| Accumulated deficit(1) | (347,560) | (314,917) | ||
| Total shareholders' equity | 325,461 | 337,663 |
(1) During the three months ended March 31, 2024, we determined that an immaterial error existed in our previously issued consolidated financial statements related to stock compensation expense on unvested shares of market-based awards of certain employees upon their termination. Our Accumulated deficit was impacted by the error by $1.6 million and was corrected within our Quarterly Report on Form 10-Q filed for the three months ended March 31, 2024.
Page 9
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BIOLIFE SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION
(Unaudited, amounts in thousands)
| Nine Months Ended<br>September 30, | ||||
|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | ||
| Net cash provided by (used in) operating activities | $ | 6,786 | $ | (14,809) |
| Net cash (used in) provided by investing activities | (15,337) | 13,880 | ||
| Net cash (used in) provided by financing activities | (2,697) | 750 | ||
| Effects of currency translation | (29) | (28) | ||
| Net decrease in cash, cash equivalents, and restricted cash | $ | (11,277) | $ | (207) |
As a result of the Company's divestiture of Global Cooling during the quarter, several financial metrics were re-forecasted to more closely align with continuing operations. During this process, several non-GAAP measures were adjusted, resulting in differences between previously reported non-GAAP results on a continuing operations basis. All adjusted items are designated with a (*) symbol.
BIOLIFE SOLUTIONS, INC.
RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP ADJUSTED GROSS MARGIN
(Unaudited, amounts in thousands)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||
| Total revenues | $ | 30,571 | $ | 23,573 | $ | 85,678 | $ | 81,992 | ||||
| Cost of revenues | (14,276) | (11,578) | (40,278) | (44,989) | ||||||||
| COGS intangible asset amortization | (577) | (733) | (1,736) | (2,199) | ||||||||
| GROSS PROFIT | $ | 15,718 | $ | 11,262 | $ | 43,664 | $ | 34,804 | ||||
| GROSS MARGIN | 51 | % | 48 | % | 51 | % | 42 | % | ||||
| ADJUSTMENTS TO GROSS PROFIT: | ||||||||||||
| Inventory reserve costs | 247 | (1,623) | 247 | 562 | ||||||||
| Loss (gain) on disposal of assets* | 4 | — | (44) | — | ||||||||
| Intangible asset amortization | 577 | 733 | 1,736 | 2,199 | ||||||||
| ADJUSTED GROSS PROFIT | $ | 16,546 | $ | 10,372 | $ | 45,603 | $ | 37,565 | ||||
| ADJUSTED GROSS MARGIN | 54 | % | 44 | % | 53 | % | 46 | % |
Page 10
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BIOLIFE SOLUTIONS, INC.
RECONCILIATION OF GAAP OPERATING EXPENSES FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED OPERATING EXPENSES FROM CONTINUING OPERATIONS
(Unaudited, amounts in thousands)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||
| OPERATING EXPENSES FROM CONTINUING OPERATIONS | $ | 32,130 | $ | 39,048 | $ | 94,193 | $ | 116,727 |
| ADJUSTMENTS TO OPERATING EXPENSES FROM CONTINUING OPERATIONS: | ||||||||
| Cost of product, rental, and service revenues | (14,276) | (11,578) | (40,278) | (44,989) | ||||
| Acquisition and divestiture costs | (442) | (250) | (833) | (3,226) | ||||
| Severance costs | — | (493) | — | (493) | ||||
| Intangible asset amortization | (910) | (1,312) | (2,734) | (4,135) | ||||
| Loss on disposal of assets | (4) | (11) | 96 | (39) | ||||
| Change in fair value of contingent consideration | — | 1,580 | — | 1,778 | ||||
| Other income | 679 | — | 979 | — | ||||
| Asset impairment charges | — | (8,310) | — | (8,310) | ||||
| ADJUSTED OPERATING EXPENSES FROM CONTINUING OPERATIONS | $ | 17,177 | $ | 18,674 | $ | 51,423 | $ | 57,313 |
Page 11
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BIOLIFE SOLUTIONS, INC.
RECONCILIATION OF GAAP OPERATING LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED OPERATING LOSS FROM CONTINUING OPERATIONS
(Unaudited, amounts in thousands)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||
| OPERATING LOSS FROM CONTINUING OPERATIONS | $ | (1,559) | $ | (15,475) | $ | (8,515) | $ | (34,735) |
| ADJUSTMENTS TO OPERATING LOSS FROM CONTINUING OPERATIONS | ||||||||
| Inventory reserve costs | 247 | (1,623) | 247 | 562 | ||||
| Acquisition and divestiture costs | 442 | 250 | 833 | 3,226 | ||||
| Severance costs | — | 493 | — | 493 | ||||
| Intangible asset amortization | 910 | 1,312 | 2,734 | 4,135 | ||||
| Loss (gain) on disposal of assets | 4 | 11 | (96) | 39 | ||||
| Change in fair value of contingent consideration | — | (1,580) | — | (1,778) | ||||
| Other income | (679) | — | (979) | — | ||||
| Asset impairment charges | — | 8,310 | — | 8,310 | ||||
| ADJUSTED OPERATING LOSS FROM CONTINUING OPERATIONS | $ | (635) | $ | (8,302) | $ | (5,776) | $ | (19,748) |
Page 12
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BIOLIFE SOLUTIONS, INC.
RECONCILIATION OF GAAP NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED NET LOSS FROM CONTINUING OPERATIONS
(Unaudited, amounts in thousands)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||
| NET LOSS FROM CONTINUING OPERATIONS | $ | (1,703) | $ | (15,804) | $ | (13,061) | $ | (30,043) |
| ADJUSTMENTS TO NET LOSS FROM CONTINUING OPERATIONS | ||||||||
| Inventory reserve costs | 247 | (1,623) | 247 | 562 | ||||
| Acquisition and divestiture costs | 442 | 250 | 833 | 3,226 | ||||
| Severance costs | — | 493 | — | 493 | ||||
| Intangible asset amortization | 910 | 1,312 | 2,734 | 4,135 | ||||
| Loss (gain) on disposal of assets | 4 | 11 | (96) | 39 | ||||
| Change in fair value of equity investments | — | — | 4,074 | — | ||||
| Change in fair value of contingent consideration | — | (1,580) | — | (1,778) | ||||
| Other income | (679) | — | (979) | — | ||||
| Income tax (benefit) expense | (28) | 115 | 93 | 209 | ||||
| Gain on settlement of Global Cooling escrow | — | — | — | (5,115) | ||||
| Asset impairment charges | — | 8,310 | — | 8,310 | ||||
| ADJUSTED NET LOSS FROM CONTINUING OPERATIONS | $ | (807) | $ | (8,516) | $ | (6,155) | $ | (19,962) |
Page 13
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com
BIOLIFE SOLUTIONS, INC.
RECONCILIATION OF GAAP NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA FROM CONTINUING OPERATIONS
(Unaudited, amounts in thousands)
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||
| NET LOSS FROM CONTINUING OPERATIONS | $ | (1,703) | $ | (15,804) | $ | (13,061) | $ | (30,043) | ||||
| ADJUSTMENTS: | ||||||||||||
| Interest expense, net | 267 | 449 | 796 | 1,216 | ||||||||
| Accretion of available-for-sale investments* | (88) | (309) | (408) | (1,048) | ||||||||
| Income tax (benefit) expense | (28) | 115 | 93 | 209 | ||||||||
| Depreciation | 1,407 | 1,788 | 4,305 | 5,261 | ||||||||
| Intangible asset amortization | 910 | 1,312 | 2,734 | 4,135 | ||||||||
| EBITDA | $ | 765 | $ | (12,449) | $ | (5,541) | $ | (20,270) | ||||
| OTHER ADJUSTMENTS: | ||||||||||||
| Share-based compensation (non-cash) | 5,324 | 7,984 | 16,022 | 19,715 | ||||||||
| Inventory reserve costs | 247 | (1,623) | 247 | 562 | ||||||||
| Acquisition and divestiture costs | 442 | 250 | 833 | 3,226 | ||||||||
| Severance costs | — | 493 | — | 493 | ||||||||
| Loss (gain) on disposal of assets | 4 | 11 | (96) | 39 | ||||||||
| Change in fair value of equity investments | — | — | 4,074 | — | ||||||||
| Change in fair value of contingent consideration | — | (1,580) | — | (1,778) | ||||||||
| Other income | (679) | — | (979) | — | ||||||||
| Gain on settlement of Global Cooling escrow | — | — | — | (5,115) | ||||||||
| Asset impairment charges | — | 8,310 | — | 8,310 | ||||||||
| ADJUSTED EBITDA FROM CONTINUING OPERATIONS | $ | 6,103 | $ | 1,396 | $ | 14,560 | $ | 5,182 | ||||
| % of Revenue | 20 | % | 6 | % | 17 | % | 6 | % |
Page 14